ABSTRACT
AIM:To evaluate the efficacy of intravitreal dexamethasone implant(DEX-I)in the treatment of different types of macular edema secondary to retinal vein occlusion(RVO).METHODS:A retrospective observational case study was conducted. A total of 46 patients(46 eyes)who were diagnosed with RVO-macular edema(ME)and received DEX-I of 0.7 mg as the initial treatment in Dalian No.3 People's Hospital from July 2019 to June 2020 were collected. According to the morphological characteristics of optical coherence tomography(OCT), they were divided into diffuse retinal thickening type(DRT type, 13 patients, 13 eyes), cystoid macular edema type(CME type, 22 patients, 22 eyes )and serous retinal detachment type(SRD type, 11 patients, 11 eyes ). The best corrected visual acuity(BCVA)and central retinal thickness(CRT)of patients with three types of macular edema were observed and compared before treatment and 1, 2 and 3mo after treatment.RESULTS:Compared with before treatment, BCVA of patients with DRT, CME and SRD were significantly improved at 1, 2 and 3mo after treatment, and CRT was significantly decreased(all P<0.017). At 3mo after treatment, BCVA(0.21±0.12, 0.22±0.10LogMAR)of DRT and SRD patients was significantly better than that of CME(0.45±0.14LogMAR, both P<0.017), and CRT(254.08±49.07, 248.92±44.19μm)was significantly lower than that of CME(314.70±92.66 μm, both P<0.017).CONCLUSIONS: DEX-I is effective in the treatment of various OCT types of macular edema secondary to RVO, and the treatment response of CME type is worse than that of DRT and SRD types.
ABSTRACT
AIM: To compare the efficacy and safety of intravitreal injection of aflibercept combined with posterior sub-fascial injection of triamcinolone acetonide in the treatment of wet age-related macular degeneration(ARMD)with poor response to anti-vascular endothelial growth factor drugs.METHODS: Retrospective cohort study. From June 2018 to May 2020, a total of 60 patients(60 eyes)with refractory ARMD who had poor response to the treatment of anti VEGF drug ranibizumab were randomly divided into the control group of aflibercept and the observation group of triamcinolone acetonide combined with aflibercept, with 30 patients(30 eyes)in each group. Once a month, the patients in the two groups received intravitreal injection of aflibercept alone or intravitreal injection of aflibercept combined with posterior sub-fascial injection of triamcinolone acetonide for three consecutive times. The changes of best corrected visual acuity(BCVA), central macular thickness(CMT)and intraocular pressure were reviewed before injection and 1, 3 and 6mo after the third injection.RESULTS: The BCVA and CMT of the two groups were significantly improved 1, 3 and 6mo after the injection of the drug(P<0.05). The mean intraocular pressure in the combined group was higher at 1mo after treatment than before, but it still within the normal range. There was a significant difference in intraocular pressure between the two groups(17.50±4.60 vs. 18.30±3.73mmHg, P<0.05).CONCLUSION: Triamcinolone acetonide injection under the posterior fascia of the eyeball combined with intravitreal injection of aflibercept in the treatment of wet ARMD can effectively reduce macular edema and improve vision, which is more safe and reliable.
ABSTRACT
@#AIM: To explore the efficacy of intravitreal injection of ranibizumab and conbercept in the treatment of exudative age-related macular degeneration(ARMD), and analyze the effects on best corrected visual acuity(BCVA), central retinal thickness(CRT)and complications of patients. METHODS: The clinical data of 60 patients(60 eyes)with exudative ARMD in the hospital between January 2017 and January 2020 were collected for retrospective analysis. According to different treatment drugs, they were divided into intravitreal injection of ranibizumab group(30 eyes)and intravitreal injection of conbercept group(30 eyes). The BCVA, CRT, choroidal neovascularization changes and occurrence of complications were compared between the two groups before treatment and 1, 2 and 3mo after treatment. RESULTS: After 1, 2 and 3mo treatment, the BCVA(LogMAR)of patients in the two groups was better than that before treatment(<i>P</i><0.05). The CRT was lower than that before treatment(<i>P</i><0.05), and the CRT at 1, 2 and 3mo after treatment in intravitreal injection of conbercept group was lower than that in intravitreal injection of ranibizumab group(<i>P</i><0.05). There were no significant differences in the recovery of choroidal neovascularization and the occurrence of complications between the two groups(<i>P</i>>0.05). CONCLUSION: Both intravitreal injection of ranibizumab and conbercept can achieve a good efficacy in the treatment of exudative ARMD, and there was no significant difference in the improvement of visual acuity between them. However, conbercept has obvious advantages in reducing CRT in the treatment of exudative ARMD.
ABSTRACT
@#AIM: To explore the long-term efficacy of vitrectomy combined with or without anti-VEGF in the treatment of proliferative diabetic retinopathy(PDR).<p>METHODS: Randomized controlled trials(RCTs)comparing the efficacy of vitrectomy combined with or without anti-VEGF therapy for PDR were retrieved from databases including PUBMED, EMBASE, Cochrane Central Register of Controlled Trials(CENTRAL)and Web of Science. The retrieval time was from the establishment of the databases to July 2020. According to the inclusion and exclusion criteria, the literature was selected, then data extraction and quality evaluation was completed. Primary evaluation measures included postoperative incidence of retinal detachment, central retinal thickness(CRT), and best corrected visual acuity(BCVA). <p>RESULTS: In this article, 11 randomized controlled studies(880 eyes)were included. Meta-analysis results showed that the incidence of retinal detachment after vitrectomy was significantly lower in PDR patients who received anti-VEGF injection before vitrectomy than in patients who did not receive anti-VEGF injection \〖Risk ratio(<i>RR</i>)=0.39, 95% Confidence interval(<i>CI</i>)0.22 to 0.71, <i>P</i>=0.002\〗. There were significant differences in the incidence of retinal detachment after vitrectomy between the anti-VEGF group and the non-VEFG group in both Asian and non-Asian populations(Asian:<i> RR</i>=0.20, 95%<i>CI</i> 0.05 to 0.87, <i>P</i>=0.03; Non-Asian:<i> RR</i>=0.46, 95%<i>CI</i> 0.24 to 0.89, <i>P</i>=0.02). The central retinal thickness of PDR patients who received preoperative anti-VEGF therapy was significantly lower than that of patients who did not receive anti-VEGF therapy 3 and 6mo after PPV(<i>MD</i>=-78.49, 95%<i>CI</i> -94.81 to -62.17, <i>P</i><0.00001. <i>MD</i>= -39.62, 95%<i>CI</i> -48.44 to -30.80, <i>P</i><0.00001). The BCVA at 6mo after PPV in PDR patients with preoperative anti-VEGF treatment was better than that in patients without preoperative anti-VEGF treatment(<i>MD</i>=-0.16, 95%<i>CI</i> -0.21 to -0.10, <i>P</i><0.00001).<p>CONCLUSION: Anti-VEGF injection before PPV can effectively reduce the incidence of retinal detachment, alleviate postoperative macular edema, reduce the central retinal thickness, and improve BCVA in PDR patients.
ABSTRACT
Aim: The aim of the study was to assess the effect of combined phacoemulsification and single intraoperative intravitrealinjection of bevacizumab on the central macular thickness (CMT) in diabetic patients.Materials and Methods: A prospective observational study was conducted on 30 eyes with diabetic retinopathy from February2018 to February 2019. All patients underwent thorough ophthalmic evaluation. Phacoemulsification performed by a singlesurgeon using either 0.5% topical proparacaine eye drops or sub-tenon local anesthesia as per the preference of the surgeonin individual case. Bevacizumab 0.05 ml (1.25 mg) was injected intravitreal using a 30-gauge needle through the pars planainto the vitreous cavity after intraocular lens implantation. Patients were followed postoperatively at day 1 then at 1 week and1 month, respectively, for recording the CMT and best corrected visual acuity at 1 month postoperatively.Results: The mean CMT for all the patients at post-operative day 1 and month 1 was 277.96 ± 142.40 μm and 289.50 ± 155.74 μm,respectively. Patients with <10 years of diabetes had mean CMT of 329.09 μm and 318.90 μm, at post-operative day 1 and at1 month, respectively, while those with diabetes more than 10 years had mean CMT of 248.36 μm and 272.47 μm, respectively.In mild non-proliferative diabetic retinopathy (NPDR) and stable proliferative diabetic retinopathy group no significant worseningoccurred in CMT thickness, while in moderate NPDR, four out of 13 cases showed significant increase in CMT (>10%) at 1 month. Insevere NPDR, out of 4 cases 1 case showed significant increase in CMT while other three cases showed modest reduction of CMT.Conclusion: Intravitreal administration of 1.25 mg bevacizumab at the time of cataract surgery is a safe and effective way inavoiding new onset maculopathy in diabetic retinopathy patients. It is also effective to treat pre-existing clinically significantmacular edema and prevent its progression to some extent in few cases.
ABSTRACT
@#AIM: To analyze both the effects of different risk factors on incidence of retinal vein occlusion and the comparison of difference between risk factors of RVO subgroups.<p>METHODS:Retrospective case control study. 79 cases of patients treated were collected as RVO group. These cases were further classified into high CRT group(26 cases)and low CRT group(53 cases)according to the CRT whether it is greater than 369μm. In the same time, 59 cases of patients who were conducted surgery of ophthalmology ward in our hospital were also collected. Statistical analysis of risk factors.<p>RESULTS: After a comparison between these factors and control group, it turns out that there are statistical differences on high blood, carotid artery plaque and HHCY in RVO group(<i>P</i><0.05). The analysis conducted on two CRT groups revealed that difference exist in obstruction site and smoking(<i>P</i><0.05).<p>CONCLUSION: Hypertension, carotid plaque and HHCY are risk factors of RVO. In the two CRT groups, the factors that may affect CRT are obstruction site and smoking.
ABSTRACT
@#AIM: To observe the efficacy of two conbercept regimens in the treatment of polypoid choroidal angiopathy.<p>METHODS: Twenty-one patients with polypoidal choroidal vasculopathy who met the inclusion criteria and were treated in our hospital were randomly divided into two groups. The group A(9 patients and 9 eyes)was treated with 3+Q12W scheme, namely, 0.5mg conbercept ophthalmic injection was intravitreally injected every 4wk for 3 consecutive times, and then 1 time every 12wk. In the group B(12 patients and 12 eyes), 3+TAE scheme was carried out, that is 0.5mg conbercept ophthalmic injection was intravitreally injected every 4wks for 3 consecutive times. The time of next injection was determined according to the evaluation results of each visit. The interval to the next visit/treatment was ≥ 4wk and ≤ 12wk. The best corrected visual acuity(BCVA), central retinal thickness(CRT)and the frequency of injection were compared between the two groups at 12 and 48wk after treatment, respectively.<p>RESULTS: BCVA of the group A was 74.78±11.23 letters and 74.67±13.94 letters at 12 and 48wk after treatment, which increased by 7.00±4.21 letters and 6.89±4.48 letters at the baseline before treatment, respectively. BCVA in the group B was 77.83±5.46 letters and 77.58±8.59 letters respectively at 12 and 48wk after treatment, which were 8.75±7.54 letters and 8.50±5.60 letters higher than the baseline before treatment. At the 12 and 48wk after injection, the average CRT in the group A was 276.33±44.34μm and 240.56±40.11μm, respectively, which were 43.22±42.21μm and 79.00±53.64μm lower than the baseline before treatment. At the 12 and 48wk after injection, the average CRT in the group B was 271.58±63.08μm and 241.00±43.91 μm, which were 57.42±45.33μm and 88.00±61.16μm lower than the baseline before treatment, respectively. The average times of intravitreal injection of conbercept were 6.00±0.00 and 7.75±1.14 times in the 3+Q12W group and the 3+TAE group, respectively.<p>CONCLUSION: Two different regimens of conbercept could reduce the CRT and improve the visual acuity of the patients with polypoidal choroidal vasculopathy. And the times of intravitreal injection in the 3+Q12W administration group were less than those in the3+TAE administration group.
ABSTRACT
@#AIM:To evaluate the short-term efficacy and safety of intravitreal dexamethasone implant(IDI)for patients with retinal vein occlusion-related macular edema(RVO-ME)by using optical coherence tomography(OCTA).<p>METHODS: Seventeen eyes in 17 patients with RVO-ME were treated with intravitreal injection of sustained-release IDI. The best corrected visual acuity(BCVA), central macular thickness(CMT)and superficial retinal vascular network were observed at baseline, 1d, 1mo, 2mo, 3mo, 4mo and 6mo.<p>RESULTS: CMT was significantly reduced from baseline by 24h after injection and improved further during the 3mo follow-up, and the improvement of visual acuity was consistent with that of CMT. OCTA showed improvement from baseline in terms of decreased number and size of cysts and restoration of the retinal vascular network. A slight increase in intraocular pressure was observed in 2 eyes after injection. There were no systemic side effects associated with injection or medication during follow-up.<p>CONCLUSION: CMT reduced as early as 24h after the injection of IDI, with further reduction during follow-up, and OCTA could visually observe the changes of retinal vascular network in macular area.
ABSTRACT
@#AIM: To observe the clinical characteristics and influence factors of different responses in patients with wet age-related macular degeneration(wARMD)treated with intravitreal conbercept.<p>METHODS: A total of 62 eyes(56 patients)with wet age-related macular degeneration who received intravitreal Conbercept injections(3+PRN)in our hospital from January to September 2018 were retrospectively analyzed. The best-corrected visual acuity(BCVA)and optical coherence tomography(OCT)were performed before and after treatment. Responses were evaluated and grouped according to BCVA after the last injection. 33 cases of 35 eyes with BCVA improvement ≥5 letters were included in the response group. 23 cases with 27 eyes were included in the non-response group. Before and after treatment, BCVA, central retinal thickness(CRT)and related data of the two groups were analyzed.<p>RESULTS: One month after 3 injections, BCVA in the response group increased from 41.83±7.92 letters at baseline to 52.52±10.61 letters(<i>t</i>= -6.883, <i>P</i>=0.02), and BCVA increased from 43.65 ± 10.42 letters at baseline to 44.18 ± 8.47 letters in the non-response group(<i>t</i>=0.471, <i>P</i>=0.684).CRT of the two groups after treatment decreased from the baseline(<i>F</i>=31.47, 27.28, all <i>P</i><0.01). Six months after 3 injections, the proportion of patients with the integrity of the macular fovea ellipsoid in response group(69%)was more than that in the non-responsive group(7%), and the proportion of patients with subretinal fluid(86%)was higher than that without SRF in the response group(44%), the proportion of patients with intraretinal fluid(31%)in the response group was lower than that in the non-response group(81%)(all <i>P</i><0.05), but there was no difference in the proportion of patients with pigment epithelial detachment between the two groups(77% <i>vs</i> 59%, <i>P</i>> 0.05).<p>CONCLUSION: Intravitreal injections of conbercept can effectively reduce the subretinal fluid and retinal fluid in patients with wet age-related macular degeneration, and improve the patient's visual acuity. Patients with the integrity of the outer layer of the retina(especially the ellipsoidal zone)and SRF responded well after treatment, while patients with IRF responded poorly after treatment.
ABSTRACT
Objective · To investigate the clinical effect of intravitreal injection of Conbercept in the treatment of diabetic macular edema (DME).Methods · Eleven patients (17 eyes) with DME (inflammatory type) received intravitreal injection of Conbercept monthly. After the first treatment, the patients were treated on demand. Follow-up after treatment for more than 6 months, the best corrected visual acuity (BCVA), central retinal thickness (CRT),diminished rate of DME and result of fundusfluorescein angiography(FFA) of DME eyes before and after treatment were compared. Results · During a follow-up of 7-29 months [(12±7) months], the injections were given 1-10 times [(4±3) times]. The results showed that the treatment effects on improving BCVA (logMAR) and diminishing of CRT were significant (t=7.306, P=0.001; t=5.272, P=0.000). The diminished rate of DME of our patients was 76.5%. Conclusion · Intravitreal injection of Conbercept in the treatment of DME is effective on reducing macular edema and improving visual acuity.
ABSTRACT
AIM: To investigate the efficiency of intravitreal ranibizumab therapy ( IVR ) for polypoidal choroidal vasculopathy ( PCV) in single or multiple polyps. METHODS: A total 63 patients diagnosed with PCV in Shaoxing City People's Hospital from May 2013 to May 2015 were enrolled and divided into single polyp group and multiple polyps group. All patients received intravitreal ranibizumab 3 monthly and were followed up for 12mo. Observe the changes of best corrected visual acuity ( BCVA ) and central retinal thickness ( CRT ) at different time points. RESULTS: The single polyps group exhibited a better BCVA, shorter greatest linear dimension, and lower prevalence of fibro - vascular pigment epithelial detachment compared with the multiple polyp group before treatment (P CONCLUSION: IVR meet better result in PCV patients with multiple polyp and polyp numbers may be valuable to prognosis.
ABSTRACT
Background The studies on intravitreal ranibizumab for diabetic macular edema (DME) primarily focuses on the absolute change of central retinal thickness, while the affection of the relative change of central retinal thickness (RCRT) or relative change of central retinal thickening (RCRTing) on visual prognosis has not been elucidated completely.Objective This study aimed to evaluate the effect of RCRT and RCRTing in assessing visual prognosis in DME patients following intravitreal injection of ranibizumab.Methods A self-controlled observational study was designed.Thirty eyes of thirty patients with clinically significant DME (CSDME) were recruited in Beijing 401 Hospital of China Nuclear Industry from November 2013 to October 2014.Ranibizumab of 0.05 ml (10 mg/ml) was intravitreally injected by 30G syringe needle at 3.5 mm posterior corneal limbus.Best corrected visual acuity (BCVA) far 2.5 meters away modified ETDRs visual chart was examined before injection and 3 and 6 months after injection,and the BCVA difference value between before injection and 6 months after injection was calculated as the absolusion BCVA (ABCVA).Spectral domian optical coherence tomography (SD-OCT) system was employed to measure the central retinal thickness (CRT) and to calculate the RCRT and RCRTing value.The correlations of RCRT or RCRTing with ABCVA was analyzed.Results The LogMAR values were (0.66±0.20) ,(0.40±0.25) BCVA and (0.37±0.25) before injection and 3,6 months after injection respectively in the CSDME patients,with a significant difference among them (F =36.79,P＜0.05).The values were obviously improved 3 and 6 months after injection compared with before injection (both at P＜0.05).The mean ABCVA (LogMar) of the patients was (0.30±0.21).The CRT 3,6 ,pmyjd sgyrt omkrvyopm values were (508.63±130.44), (331.07±71.84) and (311.77±64.47)μm before injection and respectively in the CSDME patients, showing a significant difference among them (F=49.78,P＜0.05).The CRT values were evidently reduced 3 and 6 months after injection in comparison with before injection (both at P＜0.05) ,and the mean ACRT value was (196.87±140.59) μm.The ABCVA values were (0.13±0.13),(0.44±0.14),(0.07±0.09) and (0.41±0.15) LogMAR in the RCRT＜35％ group,RCRT≥ 35％ group,RCRTing＜69％ group and RCRTing ≥ 69％ group, respectively.Significant differences were found in ABCVA between the RCRT＜35％ group and RCRT≥35％ group (t=-6.27,-8.65,both at P＜0.05).RCRT and RCRTing showed the positive correlations with ABCVA in the CSDME patients (r =0.86,0.79, P ＜ 0.05).Conclusions RCRT and RCRTing can identify well the optimal responders to intravitreal ranibizumab and predict BCVA improvement after treatment.RCRT has better association with ABCVA than RCRTing.RCRTing may be preferable when retinal thickening is more severe.
ABSTRACT
Aims: To report our experiences using Ozurdex, a biodegradable implant, containing 0.7 mg of dexamethasone in the treatment of noninfectious intermediate uveitis. Settings and Design: Retrospective study design. Methods: We conducted a retrospective study of medical records of patients with noninfectious intermediate uveitis having either cystoid macular edema (CME) or vitritis who were not responsive to standard treatment and subsequently received Ozurdex implant from March 2011 to April 2013. The outcomes measured were best‑corrected visual acuity, central retinal thickness (CRT), and vitreous haze score. Statistical Analysis Used: Paired t‑test was used to test the significance of difference between quantitative variables. A P < 0.05 is taken to denote significant relationship. Results: Twenty eyes of 15 patients with mean age of 39.8 years who received Ozurdex implant were included in the study. The mean baseline visual acuity improved from 0. 666 logarithm of the minimum angle of resolution (logMAR) units to 0.479 logMAR units at 6 weeks after the implant. The mean CRT improved from 536.1 to 361.4 microns at 6 weeks postimplant both parameters were statistically significant. The ocular inflammation was controlled in almost all the patients. Cataract and raised intraocular pressure were documented complications. Conclusion: Ozurdex implant is a promising treatment option and efficient in controlling the inflammation and CME in cases of noninfectious intermediate uveitis not responding to standard treatment.
ABSTRACT
Diabetic macular edema ( DME ) is a major cause of visual impairment in patients with diabetes mellitus, the central retinal thickness ( CRT ) is correlated with the visual impairment and the changes of visual function before and after treatment. Furthermore, CRT is related to the changes of macular microstructure. The subtle changes of retinal microstructure can be qualitative and quantitative analyzed by spectral- domain OCT ( SD -OCT) . In this study, the changes of retinal microstructure in patients with DME are reviewed, what is of great meaning to explore mechanism, observe disease progress, guide clinical treatment and prospect prognosis of DME.
ABSTRACT
PURPOSE: In the present study we analyzed the leading diseases causing epiretinal membrane and compared the prognosis after epiretinal membrane peeling. METHODS: We enrolled 158 (160 eyes) patients diagnosed with epiretinal membrane who underwent epiretinal membrane peeling from January 2005 to January 2014. The medical records including age, underlying ocular disease, and pre-operative symptoms of patients from Chonbuk National University Hospital were analyzed retrospectively. Additionally, we evaluated the changes in central macular thickness and visual acuity after the epiretinal membrane peeling. RESULTS: Idiopathic epiretinal membrane was the most common type of disease (44.4%, 71/160). The causes of secondary epiretinal membrane were diabetic retinopathy (20.6%, 33/160), retinal tear, and retinal hole (18.1%, 29/160). Other causes were post retinal detachment surgery, traumatic epiretinal membrane, retinal vein occlusion and uveitis; 6.9% (11/160), 4.4% (7/160), 3.8% (6/160), and 1.9% (3/160), respectively. The changes in central macular thickness after surgery did not differ significantly between the idiopathic epiretinal membrane and secondary epiretinal membrane patients after adjusting for age (p = 0.958, based on analysis of variance (ANOVA). Additionally, the visual acuity did not differ significantly after the surgery even after adjusting for age (p = 0.118, analysis of covariance [ANCOVA]). CONCLUSIONS: Various ocular diseases can be the leading causes of epiretinal membrane, but the leading disease does not affect the degree of central macular thickness changes after surgery or change the prognosis of post-surgical visual acuity.
Subject(s)
Humans , Diabetic Retinopathy , Epiretinal Membrane , Medical Records , Prognosis , Retinal Detachment , Retinal Perforations , Retinal Vein Occlusion , Retrospective Studies , Uveitis , Visual AcuityABSTRACT
Objetivo: examinar resultados anatómicos y visuales de los pacientes con membranas epirretinianas idiopáticas (MER) tratados mediante pelaje de membranas y su correlación funcional post-operatoria. Métodos: Estudio de serie de casos donde se revisaron las historias clínicas de 27 pacientes elegidos de manera aleatoria y a quienes se realizó pelaje de membranas epirretinianas idiopáticas con seguimiento clínico por 6 meses del post-operatorio. Al 90% (n=24) de los pacientes se les realizó cirugía combinada de facovitrectomía. Se tomaron como variables a analizar la agudeza visual pre y post-operatoria a la semana, al mes y a los 6 meses, tomografía de coherencia óptica pre y post-operatoria al mes y a los 6 meses de la cirugía. Se comparó la agudeza visual y el grosor retiniano en el milímetro central entre la medida pre y postoperatoria utilizando la prueba de t de student. Resultados: la media de agudeza visual pre-operatoria fué de 20/60 y post-operatoria (6 meses) de 20/30. La media del grosor retiniano en el milímetro central pre-operatoria resultó 409.7 micras con un valor post-operatoria (6 meses) de 341 micras. En el 82% de los pacientes se observó una mejoría en la agudeza visual post-operatoria a los 6 meses. Los pacientes con mejores agudezas visuales fueron aquellos cuya agudeza visual pre-operatoria estuvo alrededor del 20/50. Conclusiones: la agudeza visual y el grosor retiniano pre-operatorio son los mejores factores pronósticos para estimar la agudeza visual post-operatoria en pacientes operados con diagnóstico de MER. La agudeza visual post-operatoria definitiva se alcanza posterior a los 6 meses de la cirugía. Se recomienda establecer como punto de corte para la decisión quirúrgica aquellos pacientes con agudezas visuales de 20/50 o peor.
Objective: to examine anatomic and visual outcomes in patients undergoing epiretinal membrane surgery. Methods: a case series study. Twentyseven eyes from 27 patients who underwent epiretinal membrane surgery were reviewed. Correlations between preoperative and first week, one and six months post-operative bestcorrected visual acuity and Optical Coherence Tomography (OCT) findings were obtained and analyzed using t student test. Results: mean pre-operative best corrected visual acuity (BCVA) was 20/60 and six months post-op was 20/30. Mean pre-op retinal central thickness was 409.7 microns and six months post-op was 341 microns. BCVA significantly improved in 82% of the patients after six months of surgery. Patients whom achieved higher BCVA levels post-op were those with pre-op BCVA around 20/50. Conclusions: pre-operative BCVA and central retinal thickness are the most importante factors to estimate post-operative BCVA. Highest BCVA levels were achieved after six months of surgery. It is recommended to use pre-op BCVA of 20/50 as cut-off level to consider surgical treatment.